Medical manager | Sinocelltech Ltd | China
Mrs. Lixin Yan is an accomplished medical manager with extensive experience in clinical research, specializing in oncology, infectious diseases, vaccines, and metabolic products. Over the years, she has led multiple Phase IโIII clinical trials, contributing to protocol development, medical monitoring, feasibility assessment, and regulatory submissions. Her work has been instrumental in the clinical development of innovative therapies, including PD-1 inhibitors, EGFR-targeted treatments, HPV and COVID-19 vaccines, insulin, and GLP-1 products. She demonstrates strong expertise in GCP compliance, regulatory processes, and cross-functional team collaboration, ensuring high-quality research outcomes. Mrs. Yan has published impactful peer-reviewed articles, including first-author papers, highlighting her ability to generate reliable clinical evidence. Her dedication to advancing medical science through rigorous research and mentorship reflects her potential to lead future high-impact studies. Her measurable research impact is demonstrated through 68 citations, 5 documents, and an h-index of 4 according to Scopus.
Profile: Scopus
Featured Publications
1. L. Yan, J. Yi, D. Liu, J. Li, A. A. H. Baidoo, and L. Xie, “Efficacy and safety of SARS-CoV-2 neutralizing antibody, SCTA01, in high-risk outpatients diagnosed with COVID-19: A Phase II clinical trial,” Contemporary Clinical Trials Communications, 2025.